Mid급등주
M
MIRMAI Stock Diagnostic Report
Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases
Mirum Pharmaceuticals' Livmarli met the primary endpoint in a Phase 3 clinical trial for pruritus associated with a rare liver disease.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$82.56Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
Livmarli's expansion of indications and the rising value of its new drug pipeline will strengthen the company's mid-to-long-term financial growth drivers, but in the short term, financial burdens from R&D and commercialization costs remain.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Clear company-led milestones have been confirmed, including the achievement of key endpoints in the Phase 3 clinical trial of LIVMARLI, a rare liver disease treatment, and pipeline expansion.